BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act Modernizing and Ensuring Equity Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| JOHN DEOUDES | — |
| SOFIA FOX | — |
| KIRBY MILLER | — |
| LANE PENRY | — |
Trade (domestic/foreign) TRD
International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| LANE PENRY | — |
| PAUL ANTHONY WILLIAMS | — |
Health Issues HCR
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathway Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act Mental health issues Biosimilars reimbursement issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| AMY DEMSKE New | — |
| JOHN DEOUDES | — |
| STEPHANIE A. DYSON | — |
| SOFIA FOX | — |
| KIRBY MILLER | — |
| KATHRYN NOVARIA | — |
| LANE PENRY | — |
| CAROLINE TUCKER | — |
| PAUL ANTHONY WILLIAMS | — |
Medicare/Medicaid MMM
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| JOHN DEOUDES | — |
| KIRBY MILLER | — |
| KATHRYN NOVARIA | — |
| LANE PENRY | — |
| PAUL ANTHONY WILLIAMS | — |
Taxation/Internal Revenue Code TAX
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions OECD Implementation
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| JOHN DEOUDES | — |
Copyright/Patent/Trademark CPT
Intellectual Property Reform concerning bio-pharmaceutical industry
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| SOFIA FOX | — |
| LANE PENRY | — |
| PAUL ANTHONY WILLIAMS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.